Profile data is unavailable for this security.
About the company
Lee's Pharmaceutical Holdings Ltd is an investment holding company principally engaged in the development, manufacturing, marketing and sales of pharmaceutical products. The Company operates its business through two segments. The Imported Products segment is engaged in the sale of imported products. Its imported products include Keyan injection, Fipril oral solution and others. The Proprietary Products segment is engaged in the manufacture and sale of self-developed products. Its R&D products include Resilicon Tablets, ADASUVE Inhalation Powder and others. The Company's medicines cover the fields of cardiovascular and infectious diseases, dermatology, oncology, gynecology and ophthalmology. The Company mainly operates its business in mainland China, Hong Kong and Taiwan.
- Revenue in HKD (TTM)1.20bn
- Net income in HKD63.06m
- Incorporated2001
- Employees993.00
- LocationLee's Pharmaceutical Holdings LtdUnit 110-111, Bio-Inf. Centre,No.2 Science Park West Avenue,Hong Kong Science Park, Shatin Hong KongHKG
- Phone+852 23141282
- Fax+852 23141708
- Websitehttps://www.leespharm.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Uni-Bio Science Group Ltd | 508.40m | 98.86m | 382.14m | 458.00 | 3.90 | 1.22 | 3.21 | 0.7517 | 0.0159 | 0.0159 | 0.0812 | 0.0507 | 1.27 | 2.23 | 12.21 | 1,249,140.00 | 24.76 | 1.46 | 32.97 | 1.97 | 83.51 | 80.59 | 19.44 | 1.23 | 2.17 | 168.55 | 0.2267 | 0.00 | 10.08 | 29.08 | 84.04 | -- | 84.98 | -- |
Tianda Pharmaceuticals Ltd | 384.68m | -47.26m | 387.01m | 695.00 | -- | 0.7107 | -- | 1.01 | -0.022 | -0.022 | 0.1789 | 0.2533 | 0.4341 | 2.97 | 4.46 | 445,745.10 | -5.34 | -- | -7.97 | -- | 45.83 | -- | -12.30 | -- | 0.6748 | -9.51 | 0.1536 | -- | -- | -- | -- | -- | -- | -- |
3D Medicines Inc | 525.09m | -483.09m | 521.58m | 193.00 | -- | 0.5727 | -- | 0.9933 | -2.05 | -2.05 | 2.20 | 3.53 | 0.3746 | 4.94 | 5.79 | 2,651,946.00 | -37.27 | -- | -50.88 | -- | 91.97 | -- | -99.50 | -- | 2.56 | -- | 0.2517 | -- | 11.91 | -- | 48.78 | -- | -- | -- |
Fusen Pharmaceutical Co Ltd | 457.06m | -96.33m | 665.37m | 1.14k | -- | 1.21 | -- | 1.46 | -0.1292 | -0.1292 | 0.6136 | 0.7455 | 0.3212 | 1.68 | 5.01 | 398,137.50 | -6.77 | 0.9678 | -13.96 | 1.74 | 53.18 | 51.95 | -21.08 | 2.59 | 0.526 | -2.10 | 0.4031 | 27.95 | 15.02 | 4.13 | -4.83 | -- | 0.2124 | -- |
Lee's Pharmaceutical Holdings Ltd | 1.20bn | 63.06m | 724.27m | 993.00 | 11.49 | 0.4227 | 3.69 | 0.604 | 0.1071 | 0.1071 | 2.04 | 2.91 | 0.4403 | 2.11 | 9.70 | 1,134,410.00 | 1.98 | 13.33 | 2.52 | 17.76 | 51.49 | 61.92 | 4.50 | 36.20 | 0.7425 | 6.58 | 0.132 | 3.59 | -14.61 | -1.53 | -67.44 | -47.49 | -12.19 | -31.34 |
Zhaoke Ophthalmology Ltd | 61.46m | -243.91m | 742.75m | 297.00 | -- | 0.3401 | -- | 12.09 | -0.4478 | -0.4478 | 0.1128 | 4.00 | 0.0233 | 1.25 | 16.09 | 196,357.80 | -9.23 | -- | -10.51 | -- | 82.03 | -- | -396.86 | -- | 5.48 | -24.02 | 0.1114 | -- | -- | -- | 5.47 | -- | -- | -- |
Pak Fah Yeow International Ltd | 265.21m | 96.45m | 760.40m | 101.00 | 7.89 | 1.01 | 7.33 | 2.87 | 0.3094 | 0.3094 | 0.8507 | 2.41 | 0.2869 | 2.84 | 23.53 | 2,600,118.00 | 10.44 | 3.99 | 11.32 | 4.18 | 87.05 | 80.79 | 36.37 | 21.27 | 4.22 | 5.26 | 0.0055 | 100.68 | 76.06 | 12.94 | 250.66 | 23.02 | 18.83 | -8.06 |
Zhongzhi Pharmaceutical Holdings Ltd | 2.20bn | 119.57m | 777.24m | 2.74k | 6.37 | 0.6538 | 3.36 | 0.354 | 0.1412 | 0.1412 | 2.59 | 1.38 | 1.09 | 2.68 | 7.39 | 830,705.70 | 5.99 | 7.69 | 9.17 | 11.75 | 57.55 | 60.44 | 5.49 | 6.73 | 0.9033 | 213.59 | 0.1516 | 42.46 | 12.26 | 12.41 | 53.00 | 13.86 | 17.65 | -- |
Jilin Provnc Hnn Chnglng Bio-pharm CoLtd | 901.25m | 184.38m | 789.95m | 678.00 | 4.28 | 0.4641 | 6.38 | 0.8765 | 0.3291 | 0.3291 | 1.61 | 3.04 | 0.3574 | 2.10 | 2.94 | 1,062,796.00 | 7.31 | 7.67 | 10.25 | 10.48 | 75.46 | 78.79 | 20.46 | 20.68 | 1.62 | -- | 0.0502 | 7.22 | -0.0049 | 5.38 | -23.43 | -1.67 | -1.14 | -- |
Hbm Holdings Ltd | 562.02m | 165.78m | 979.73m | 158.00 | 5.68 | 0.9833 | 5.00 | 1.74 | 0.2253 | 0.2253 | 0.7623 | 1.30 | 0.3258 | 3.96 | 16.67 | 3,175,272.00 | 9.59 | -54.61 | 13.25 | -66.04 | 95.57 | 97.81 | 29.42 | -400.28 | 3.44 | 8.14 | 0.3502 | -- | 120.13 | 127.06 | 116.61 | -- | -12.62 | -- |
Holder | Shares | % Held |
---|---|---|
UBS Switzerland AG (Investment Management)as of 14 Oct 2024 | 29.33m | 4.98% |
Fidelity Management & Research Co. LLCas of 20 Feb 2023 | 29.20m | 4.96% |
Dimensional Fund Advisors LPas of 07 Nov 2024 | 6.06m | 1.03% |
Dimensional Fund Advisors Ltd.as of 31 Aug 2024 | 277.97k | 0.05% |
Acadian Asset Management LLCas of 30 Sep 2024 | 127.35k | 0.02% |
Carne Global Fund Managers (Ireland) Ltd.as of 31 Mar 2023 | 112.06k | 0.02% |
Mercer Global Investments Europe Ltd.as of 30 Jun 2023 | 95.00k | 0.02% |
Lazard Asset Management LLCas of 31 Oct 2024 | 86.11k | 0.02% |
FIL Investments Internationalas of 30 Jun 2024 | 50.00k | 0.01% |
Victory Capital Management, Inc. (Investment Management)as of 30 Jun 2024 | 45.55k | 0.01% |